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Malignant fibrous histiocytoma (MFH) is a morphologically ill-defined tumour of
the soft tissues and may involve nearly every organ of the body. MFH of the
spermatic cord represents an extremely rare entity and reports of it in the litera-
ture are limited. We report a 69-year-old man found to have a left spermatic
cord MFH and retroperitoneal and mediastinal lymphadenopathy, who was treat-
ed with radical orchiectomy and adjuvant chemotherapy. The morphological
findings of the spermatic tumour are presented and the literature is reviewed to
clarify the potential diagnostic/therapeutic approaches and the prognosis relat-
ed to spermatic cord MFH.
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INTRODUCTION
Since it was described in 1964 by O’Brien and
Stout [34], malignant fibrous histiocytoma (MFH) has
represented an ill-defined entity, comprising five or
six histological subtypes (pleomorphic-storiform, gi-
ant-cell, inflammatory, fibrous, myxoid and angiom-
atoid), which partially differ both clinically and prog-
nostically [20, 35]. Although it has been hypothe-
sised that these variants manifest the common mor-
phological patterns of a heterogeneous group of
poorly differentiated tumours, there are still con-
troversies regarding the concept of MFH as a dis-
tinct tumour entity [1, 5, 11, 15, 20, 31]. The pleo-
morphic, giant-cell and inflammatory variants each
represent heterogeneous diagnostic groups that are
hard to defend as a cohesive entity, while the myx-
oid (myxofibrosarcoma) and angiomatoid types are
rather reproducible tumour types. It is quite possi-
ble that a number of cases of MFH have been for-
merly classified as pleomorphic liposarcoma or ple-
omorphic rhabdomyosarcoma [40] because of their
intracellular fat-laden lipoblast-like or large eosino-
philic cells. Although a matter of debate, MFH is still
widely accepted as a discrete clinicopathological en-
tity. This supports the hypothesis that MFH is a mor-
phological modulation in the tumoral progression of
other sarcomas, particularly leiomyosarcomas.
The pleomorphic subtype of MFH is regarded as
the most common soft tissue sarcoma of adulthood.
However, there are currently no definable criteria for
its diagnosis. In fact, several recent studies have ex-
pressed considerable doubts regarding MFH, or at
least its pleomorphic type, as a distinct entity and
have suggested that it represents a common mor-
phology of a group of poorly differentiated sarco-
mas [15, 16] and, more rarely, other neoplasms. Fea-
tures generally considered characteristic of pleomor-
phic MFH include cells arranged in a storiform pattern
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with frequent giant cells and an area of pleomor-
phism and intense anisonucleosis [35]. While 70%
of MFHs arise as a primary tumour, others are asso-
ciated with pre-existing conditions such as radiation
therapy or fracture [22, 40]. Malignant fibrous histi-
ocytoma shows a distinct gender predilection with
an approximate male to female ratio of 2 to 1. Its high-
est incidence is during the fifth decade of life [22].
Malignant fibrous histiocytoma has a high propen-
sity for local recurrence (44%) and distant metasta-
sis (42%) [51].
Here we report a patient with MFH of the sper-
matic cord. Known as a connective tissue neoplasia,
MFH may occasionally involve such organs as the
spleen, heart, colon, breast, ovary, testes, kidney (or
its capsule), trachea, thyroid gland, vulva and glans
penis [1, 12, 13, 19, 23–25, 33, 36, 38, 50, 52]. Sper-
matic cord MFH is an extremely rare tumour, first
reported by Cole et al. [8]. We now review the liter-
ature on this rare finding.
CASE REPORT
A 69-year-old man with a history of hyperten-
sion and cigarette smoking (65 packs per year) since
early childhood sought medical consultation because
of left scrotal enlargement of one month’s duration.
Physical examination showed a painless mass sur-
rounding the left spermatic cord, making it difficult
to palpate.
A spermatic cord tumour being suspected, a left
radical inguinal orchiectomy was performed. Gross-
ly, the specimen consisted of a yellow elastic mass
measuring 15 × 7 × 6 cm. Its cut section showed
a solid mass of 7 cm in diameter filling and surround-
ing the spermatic cord. Microscopic inspection of
the tumour revealed extensive necrotic areas involv-
ing the spermatic cord and a proliferation of spin-
dle-type cells in a storiform pattern. These spindle
cells were of an unusual morphology with severe
nuclear pleomorphism and hyperchromasia as well
as atypical mitotic figures (Fig. 1). Scattered mitoses
were identified at 5–6 per 10× high-powered fields.
A high-grade MFH (pleomorphic storiform subtype)
of the spermatic cord was diagnosed. Post-opera-
tive abdominal computed tomography demonstrat-
ed retroperitoneal and mediastinal lymph-node en-
largement. Subsequently the patient received two
courses of chemotherapy, of four and twelve weeks
respectively, following orchiectomy. Chemotherapy
(mesna 500 mg/m2/day × 4 days, doxorubicin 20 mg/m2/
/day × 3 days, ifosfamide 2500 mg/m2/day × 3 days
and dacarbazine 3000 mg/m2/day × 3 days) was
tolerated and the patient is currently doing well. At
a follow-up of 18 months no signs of local recur-
rence or metastasis were identified.
DISCUSSION
Malignant fibrous histiocytoma is the most
common soft-tissue tumour in adults [35] and, as
mentioned before, can be found in nearly every
organ of the body. However, its occurrence in the
spermatic cord represents a very rare entity. Near-
ly 80% of spermatic cord MFHs occur in patients
who are older than 50 years. Spermatic MFH usu-
ally presents as a slowly growing, painless, well-
circumscribed solitary mass in the scrotum inguinal
region and may distinctly encircle the spermatic
cord [27, 30]. Reported sizes range from less than
1 cm to more than 20 cm at presentation [21, 27, 30].
The largest tumour of spermatic cord MFH, with a di-
ameter of 27 cm, was reported in a holocaust sur-
vivor who had been subjected to unethical Nazi
medical experimentation by intratesticular injec-
tion with an unknown substance [45]. The mass
related to the spermatic MFH may present for
weeks, months or years before coming to medical
attention [46]. MFH may be painful, depending on
the histological subtype (inflammatory or giant-
cell MFH for example) [21].
Diagnosis
Currently, excisional biopsy and microscopic ex-
amination of tissue specimens are considered to be
the gold-standard method for the diagnosis of MFH.
Grossly, the specimen is frequently a well-circum-
scribed, yellowish solid tumour. Spermatic cord MFH
may infiltrate the vas deferens, pampiniform plexus
and adjacent adipose tissues [32]. The epididymis
and testis are characteristically not infiltrated, with
the exception of neglected cases and the giant-cell
subtype of MFH [21, 32, 45, 47]. Approximately 25%
of specimens demonstrate a satellite nodule at
presentation, conveying a worse prognosis [17]. His-
topathologically, 83% of spermatic cord MFH are of
the pleomorphic subtype, 9% giant-cell and 6% of the
inflammatory and, very rarely, myxoid subtypes [27].
Ultrastructural or immunohistochemical features
have also been applied for diagnosing a MFH. Im-
munohistochemistry displays vimentin reactivity and
negativity for keratins and leukocytic common an-
tigen [4].
Recently, a combination of fine-needle aspiration
(FNA) for cytological examination and immunohis-
tochemistry was applied to examine a patient with
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Figure 1. Micrographs of the spermatic malignant fibrous histiocytoma; storiform pattern spindle cells of unusual morphology, severe nuclear pleo-
morphism and hyperchromasia and atypical mitotic figures can be seen (A). Focal inflammatory infiltration and occasional giant cells (B) are found.
B
A
a spermatic cord mass and surprisingly demonstrat-
ed a pleomorphic subtype of MFH [4]. FNA of this
lesion demonstrated bloody fluid with several small
tissue fragments. A pleomorphic appearance and
marked anaplasia as well as vimentin reactivity were
found on cytological examination of these fragments,
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confirming the diagnosis of spermatic cord MFH of
the storiform subtype. This finding, later confirmed
by surgical excision and histological examination,
confirmed the results obtained from FNA. The au-
thors suggested that a FNA combined with immu-
nohistochemical studies may replace the gold-stan-
dard open biopsy in the diagnosis of a spermatic
cord MFH [4].
The ultrasonographic appearance of a spermatic
cord MFH may closely resemble that of tumours else-
where in the body as a lobulated and heterogeneous
mass [17, 18, 21]. However, these signals are not
specific for MFH. The MRI sensitivity and specificity
for detecting a MFH are 96% and 83%, respectively
[29, 30, 49].
Prognosis and treatment
Owing to its location, the prognosis and man-
agement of spermatic MFH appear to differ from
that of a tumour of this type in other locations
[17, 42, 48]. It seems that spermatic MFH has a more
favourable prognosis even for larger lesions [17, 48],
the prognosis being more related to histological
subtype than tumour size. The rate of local recur-
rence and distant metastasis are 34.5% and 17.2%,
respectively [30]. The five-year survival rate is about
20% [10].
Radical inguinal orchiectomy, along with a wide
en bloc resection of adjacent soft tissue, has been
used for spermatic MFH [17, 35]. Regional radiation
therapy, said to be a useful adjuvant therapy, has
also been used for the prevention of local recurrenc-
es [17, 35]. More conservative therapy, such as tu-
morectomy, has also been used for masses smaller
than 8 cm [48]. Chemotherapy is infrequently used
for spermatic cord MFH, as its benefits are unknown
in view of the limited reports available. A combina-
tion of therapies has been used with a favourable
outcome for the treatment of the inflammatory type
of spermatic cord MFH [41]. In the present case there
was retroperitoneal lymphadenopathy that led us to
initiate systemic chemotherapy. Table 1 demon-
strates reported cases of spermatic MFH with the
emphasis on their treatment plan. The induction of
autoimmune disease against tumour-specific
„neoantigens” seems to be another promising po-
tential modality of treatment that could hypotheti-
cally be used for spermatic MFH and is currently under
investigation.
As mentioned earlier, the prognosis of spermatic
MFH differs from that of tumours of this kind in oth-
er locations [2, 6, 7, 26, 28, 37, 39, 43]. Metastases
may develop late in the lungs or mesentery. Intra-
abdominal lymphadenopathy and distant metastasis
to the lung or mesentry could be assessed initially
and followed with computed tomography, especial-
ly in patients with a worse prognosis and a higher
risk of progression.
In conclusion, spermatic cord MFH, a rare tumour
of this location, should be considered in the differ-
ential diagnosis of scrotal, inguinal and/or spermat-
ic cord masses [3, 9, 14, 44]. Clinicians and surgeons
should have a thorough knowledge of spermatic cord
malignant fibrous histiocytoma.
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